InsidersTradesSigma
Track the UNITED THERAPEUTICS Corp stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, UNITED THERAPEUTICS Corp has published 1,889 public disclosures. Market capitalisation: €22.1bn. The latest transaction was filed on 31 August 2026 (Levée d'options). Among the most active insiders: ROTHBLATT MARTINE A. All data is openly available.
In the past 90 days, UNITED THERAPEUTICS Corp reported a total of 500 insider trading declarations, with a total selling amount of approximately 181 million euros and no buying activity. The top insider, MARTINE A ROTHBLATT, who serves as Chairperson and CEO, has made 455 declarations totaling approximately 213 million euros. Other notable insiders include PAUL A MAHON, EVP & General Counsel, with 29 declarations totaling around 14 million euros, and JAN MALCOLM, a Director, with 2 declarations totaling approximately 156 thousand euros. The most significant recent sales by ROTHBLATT include transactions on July 31, August 4, and July 8, 2026, with amounts ranging from approximately 1.6 million to over 2.2 million euros. MAHON also sold shares on July 16, 2026, for about 1.5 million euros.
Auto-generated summary, refreshed daily.Updated 2d ago
1,889
Insider Decl.
n/a
Thresholds
€341
1 ops.
Buy Volume
€479m
1160 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate UNITED THERAPEUTICS Corp Buy (bullish), based on 12 analysts. Average price target: US$664.33.
38Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 2,300 of 29,053 companies
75.9
score / 100
Value61
Quality91
FCF yld4.7%
Earn yld6.0%
EV/EBITDA12.3x
ROE19%
Gross mgn88%
Net mgn42%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 31 August 2026
Declarations1,889 total
9,500 shares@ US$135.42Common StockSEC:0001106578-26-000131:0
480 shares@ US$514.257Common StockSEC:0001106578-26-000131:1
1,630 shares@ US$515.4587Common StockSEC:0001106578-26-000131:2
2,386 shares@ US$516.1571Common StockSEC:0001106578-26-000131:3
1,486 shares@ US$517.1073Common StockSEC:0001106578-26-000131:4
1,346 shares@ US$518.1434Common StockSEC:0001106578-26-000131:5
412 shares@ US$519.1925Common StockSEC:0001106578-26-000131:6
751 shares@ US$520.2975Common StockSEC:0001106578-26-000131:7
286 shares@ US$521.5815Common StockSEC:0001106578-26-000131:8
517 shares@ US$522.4022Common StockSEC:0001106578-26-000131:9
6 shares@ US$523.425Common StockSEC:0001106578-26-000131:10
200 shares@ US$524.4175Common StockSEC:0001106578-26-000131:11
9,500 shares@ US$135.420.0058% mcap0.2% of flowCommon StockSEC:0001106578-26-000130:0
704 shares@ US$513.40120.0016% mcap0.1% of flowCommon StockSEC:0001106578-26-000130:3
120 shares@ US$514.32010.0003% mcap0.0% of flowCommon StockSEC:0001106578-26-000130:4
240 shares@ US$515.32990.0006% mcap0.0% of flowCommon StockSEC:0001106578-26-000130:5
280 shares@ US$517.07030.0007% mcap0.0% of flowCommon StockSEC:0001106578-26-000130:6
642 shares@ US$512.47140.0015% mcap0.1% of flowCommon StockSEC:0001106578-26-000130:2
120 shares@ US$531.120.0003% mcap0.0% of flowCommon StockSEC:0001106578-26-000130:18
494 shares@ US$511.57510.0011% mcap0.0% of flowCommon StockSEC:0001106578-26-000130:1
200 shares@ US$518.8940.0005% mcap0.0% of flowCommon StockSEC:0001106578-26-000130:7
1,003 shares@ US$520.2340.0024% mcap0.1% of flowCommon StockSEC:0001106578-26-000130:8
477 shares@ US$521.23560.0011% mcap0.0% of flowCommon StockSEC:0001106578-26-000130:9
280 shares@ US$522.40290.0007% mcap0.0% of flowCommon StockSEC:0001106578-26-000130:10
240 shares@ US$523.600.0006% mcap0.0% of flowCommon StockSEC:0001106578-26-000130:11
25 of 1889 declarations
About UNITED THERAPEUTICS Corp
United Therapeutics Corp. (ticker: UTHR) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States, with its principal headquarters in Silver Spring, Maryland. Founded in 1996, the company has built a focused franchise around pulmonary vascular disease and select rare diseases, giving it a specialized market position with relatively defensive characteristics and a revenue base concentrated in a handful of recognizable brands. The core business is centered on therapies for pulmonary arterial hypertension (PAH) and, more recently, pulmonary hypertension associated with interstitial lung disease (PH-ILD). Key commercial products include Tyvaso and Tyvaso DPI, Remodulin, Orenitram, and Adcirca. United Therapeutics also markets Unituxin, an FDA-approved antibody therapy for high-risk neuroblastoma, a rare pediatric cancer. This product mix makes the company stand out: it combines orphan-disease exposure with high-value specialty pharmaceuticals, while remaining highly dependent on execution in commercialization, reimbursement access, and intellectual-property protection. From a historical perspective, United Therapeutics was founded in 1996 and has evolved from a niche therapeutics company into a broader biopharmaceutical group. The company emphasizes research, clinical development, and pipeline expansion, which are intended to extend the life cycle of existing franchises and create future growth drivers. Its geographic footprint remains predominantly U.S.-based, with a major operational presence in Silver Spring and an additional hub in Research Triangle Park, North Carolina. Competitively, United Therapeutics has established a strong position in PAH through brand recognition, clinical expertise, and long-standing relationships with specialist prescribers. Management highlights its capabilities in inhaled and prostacyclin-based therapies, where differentiation depends not only on efficacy but also on ease of administration and patient support. The portfolio is concentrated, but it supports meaningful cash flow visibility and a durable specialty-pharma profile. Recent highlights include the company’s report in July 2025 of record quarterly financial results, driven by double-digit growth in products such as Tyvaso DPI, nebulized Tyvaso, Orenitram, and Unituxin. Investors should nevertheless monitor pipeline milestones, potential competition across key franchises, and evolving regulatory dynamics. Overall, UTHR remains a high-quality healthcare/pharma name with a niche growth profile, listed on the NASDAQ in the United States and anchored by specialty respiratory and rare-disease franchises.
